Skip to main content
OpenTrials
Completed

NCT Number: NCT01497405

WHC+ (Women's Health CoOp PLUS)

This study compares the effects of standard HIV test, treat and retain (TTR) practices with TTR plus a woman-focused enhanced strategy--Women's Health CoOp (WHC+) intervention) targeting hard-to-reach and vulnerable alcohol and other drug (AOD)-using women to determine if the WHC+ intervention is more efficacious than TTR alone in reducing HIV risk behavior. Additionally, the study will determine whether HIV positive women in the WHC+ arm are more likely to follow through with referrals for further medical evaluation and linkages to HIV treatment and other care than women in the TTR arm.

Completed

Looking for future studies?

Notify Me

Key information

Age range

15 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Wesley Community Centre, Pretoria, South Africa

Loading trial locations.

About this study

There is growing recognition that no single strategy will be sufficient to eliminate transmission. In light of evidence that neither existing biomedical interventions nor any existing behavioral interventions will be sufficient to control the HIV epidemic in South Africa, the proposed study will combine a biomedical intervention with an evidence-based behavioral intervention (i.e., the Women's Health CoOp) to maximize the efficacy of both strategies. If this combination intervention proves efficacious, there is a high likelihood that it can be widely implemented, be sustainable and have a substantial public health impact by reducing the exceedingly high HIV incidence in South Africa.

The overarching goal of the proposed research is to determine whether this enhanced combination prevention strategy targeting vulnerable AOD-using women is more efficacious than current standard practices. The specific aims of the proposed study are:

Aim 1: To expand the WHC outreach strategies to reach more alcohol and other drug (AOD) - using vulnerable women in Pretoria, South Africa.

Aim 2: To test whether adding WHC to standard Treat, Test, and Retain (TTR) practices results in more HIV-positive AOD-using women getting medical evaluations (e.g., cluster of differentiation 4 (CD4), viral load), starting treatment, staying in treatment and in greater reductions in risk behaviors (e.g., AOD use, condom use, victimization) among all women-positive or negative.

The study uses a geographical cluster randomized design. Hotspots (i.e. places where sex workers and drug using women congregate) in the city of Pretoria and the surrounding areas were mapped using geographic information system (GIS) software. Fourteen hotspots were identified and geocoded. The entire area was divided into 14 zones, each of which included a hotspot. Seven matched pairs of zones were created based on socio-economic conditions and estimates of the numbers of sex workers and drug-using women residing in them. Zones within pairs were randomized to the TTR arm or the WHC+ arm. Participants are recruited by outreach workers and their intervention condition is based on the zone from which they were recruited. At study enrollment/baseline, eligible participants complete a questionnaire and baseline HIV, drug and pregnancy testing. Follow-up data collection will be conducted at 6-months and 12-months post-baseline.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female
  • Black/African
  • 15 years or older (if under 18, must be able to sign assent)
  • Use at least one of the following drugs: alcohol, marijuana (dagga), methamphetamine (tik), Mandrax (methaqualone), cocaine (crack and/or powder), heroin (Thai White), inhalants (glue and benzene) methylenedioxymethamphetamine (MDMA -ecstasy), lysergic acid diethylamide (LSD), or Kat/cat, Nyaope (a mixture of marijuana and heroin) - weekly in the past 90 days
  • Have had unprotected vaginal sex with a male partner in the last six months
  • Able to speak English, Sesotho, Tswana, or Zulu
  • Consent to HIV rapid testing and drug testing
  • Provide written verbal and assent/consent to participate
  • Able to provide verifiable locator information for the Tshwane area and plan to stay there in the next 12 months

Exclusion criteria

  • Males
  • Individuals who do not self-identify as Black/African

Treatment and study plan

Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)

Behavioral

TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).

Test, Treat, Retain(TTR) only

Biological

TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.

Primary outcomes

  1. Unprotected intercourse among women

    Time frame: 6 months

    Percentages of condom use at last sex

  2. Unprotected intercourse among women

    Time frame: 12 months

    Percentages of condom use at last sex

Secondary outcomes

  1. Medical evaluation initiation amongst HIV-positive

    Time frame: 6 months

    Percentages of HIV-positive women receiving medical evaluations.

  2. Medical evaluation initiation amongst HIV-positive

    Time frame: 12 months

    Percentages of HIV-positive women receiving medical evaluations.

  3. Treatment initiation and retention amongst HIV-positive women

    Time frame: 6 months

    Percentages of HIV-positive women starting and staying in treatment

  4. Treatment initiation and retention amongst HIV-positive women

    Time frame: 12 months

    Percentages of HIV-positive women starting and staying in treatment

  5. HIV viral load among HIV-positive women who meet criteria for antiretroviral treatment (ART) and who produce medical records with HIV viral loads

    Time frame: 6 months

    HIV viral load from medical record

  6. HIV viral load among HIV-positive women who meet criteria for antiretroviral treatment (ART) and who produce medical records with HIV viral loads

    Time frame: 12 months

    HIV viral load from medical record

  7. Alcohol use

    Time frame: 6 months post intervention

    Frequency of alcohol use in previous 30 days measured by Revised Risk Behavior Assessment (RRBA) and breath test

  8. Alcohol use

    Time frame: 12 months post intervention

    Frequency of alcohol use in previous 30 days measured by Revised Risk Behavior Assessment (RRBA) and breath test

  9. Victimization

    Time frame: 6 months post intervention

    Percentages of women who report being beaten, attacked with a weapon, or forced to have sex in the previous 90 days

  10. Victimization

    Time frame: 12 months post intervention

    Percentages of women who report being beaten, attacked with a weapon, or forced to have sex in the previous 90 days

Sponsors and collaborators

Lead sponsor

RTI International

Other

Collaborators

  • University of North Carolina, Chapel Hill

Registry information

Official study title

Combination Prevention for Vulnerable Women in South Africa

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Dec 22, 2011
Registry last updated
Jan 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.